Navigation Links
Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma
Date:9/16/2009

DENVER, Colorado and JERUSALEM, September 16 /PRNewswire/ -- Children's Hospital of Colorado and the Gamida Cell-Teva Joint Venture announced today that Children's Hospital is enrolling patients for the ExCell study. Children's Hospital is the 24th in a series of cord blood transplant sites worldwide, five of which are children's centers, participating in the study in the U.S., Spain, Italy, Hungary and Israel. The trial is researching the safety and efficacy of StemEx as a therapeutic treatment for patients with blood cancers like leukemia and lymphoma.

StemEx is a graft of blood-forming stem/progenitor cells, derived from a single unit of umbilical cord blood and expanded in culture. The graft is composed of non-embryonic stem cells committed to blood formation. The StemEx product is transplanted in combination with non-expanded cells from the same unit. StemEx is being developed by a Joint Venture of Gamida Cell and Teva Pharmaceutical Industries (NASDAQ: TEVA).

"ExCell is an important trial that gives us an opportunity to investigate alternative treatments for blood cancers. We also think it is important that the medical and patient communities are aware of the existence of this trial. Naturally, our team is available for consultation should a referring physician believe this could be the appropriate next step for a patient with leukemia or lymphoma," said Roger Giller MD, principal investigator at The Children's Hospital in Denver, Colorado.

Currently, bone marrow transplantation serves as a life-saving treatment for many types of leukemia and lymphoma. According to the National Marrow Donor Program (NMDP) 70% of patients are unable to find a matched donor in their family but are able to turn to international bone marrow transplant registries to search for an unrela
'/>"/>

SOURCE Gamida Cell LTD
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
2. The MedZilla Report for August 2009 -- Health Care Grows Another 28,000 While Hospitals And Insurers Feel Painful Pinch
3. Childrens Hospital Oakland Standardizes to Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Technology
4. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing
5. SmartGenes Services for Faster, More Precise Identification of Bacteria and Fungi to be Used by The Johns Hopkins Hospital
6. St. Johns Hospital Acquires Latest Technology in Robotic-Assisted Surgery
7. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
8. Quantros ACE Helps East Jefferson General Hospital Achieve Best-in-Class Performance
9. USC Hospitals Extend Relationship With Quantros to Manage Compliance and Risk
10. BioNeutrals Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
11. Stem Cell Cord Blood Banking Is Huge Global Business for Hospitals, Says CEO of Bio-Matrix Scientific Group Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... North American crystal oscillator market report defines and segments ... of revenue. This market was valued at $531.4 million ... by 2018, at a CAGR of 3.3% from 2013 ... North American crystal oscillator market report, to get an ... a glimpse of the segmentation of the market, and ...
(Date:10/22/2014)... San Diego, CA (PRWEB) October 22, 2014 ... laboratory balances from Sartorius, A & D Weighing, ... Sartorius CPA Semi-Micro Balance . The Sartorius ... looking for an affordable high-quality, precise, and user-friendly ... in manufacturing of laboratory equipment, their laboratory balances ...
(Date:10/22/2014)... 2014   Synthetic Biologics, Inc. (NYSE MKT: ... serious infections and diseases, announced today that the U.S. ... Allowance for a composition of matter patent application that ... program, SYN-004. This is Synthetic Biologics, first allowed patent ... adds to the Company,s extensive C. difficile ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
Breaking Biology Technology:The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... PARIS and LAUSANNE, Switzerland, September 7 ... Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical,group of ... prescription drugs that,target unmet medical needs, announced today ... granted an exclusive worldwide license to develop,and commercialise ...
... manufacture hydroxyapatite (HA) could be used to make stronger, ... University of Birmingham this week (7-10 September) presented work ... University, Edinburgh. Using Serratia bacteria, the ... surfaces such as titanium alloy, polypropylene, porous glass and ...
... Sept. 6 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, ... biotechnology company,focused on researching, developing, manufacturing and marketing,biopharmaceutical ... of,shareholders of 3SBio Inc. will be held on ... No.3 A1, Road 10, Shenyang Economy & Technology ...
Cached Biology Technology:Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 2Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 3Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 4Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent 53SBio Inc. to Hold 2009 Annual General Meeting on October 12, 2009 2
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/15/2014)... Alt will be awarded the 44th Rosenstiel Award for ... his pioneering research exploring the mechanisms of genomic instability ... cells. Alt is the second alumnus to win the ... Prize in 2003. , Alt is the Charles A. ... Harvard Medical School and an investigator at the Howard ...
(Date:10/14/2014)... N.C. – Like discriminating thieves, prostate cancer tumors scavenge ... the body. But such avarice may be a fatal ... a way to kill prostate cancer cells by delivering ... selectively destroys the diseased cells brimming with the mineral, ... uses two drugs already commercially available for other uses, ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Prostate cancer's penchant for copper may be a fatal flaw 2
... Rainmakers, Inc., an intellectual property holding company and advanced ... its "stealth" mode and is prepared to actively commercialize ... security offerings. , During the past four years, the ... develop and deploy a series of core--but expandable--technologies built ...
... up 45 percent of blood, normally take the shape of ... can sometimes deform into an asymmetrical slipper shape. A ... flow might be responsible for this deformation, as well as ... could help understand the mechanisms involved in arterial disease and ...
... CAMDEN Contrary to a national trend, more and ... major in math and science. Thanks to a $307,277 ... students in the sciences at RutgersCamden will receive unprecedented ... of their degrees. Through a new RutgersCamden program ...
Cached Biology News:Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3NSF grant supports Rutgers-Camden program for science majors 2NSF grant supports Rutgers-Camden program for science majors 3
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
... PAGE Cleavable ICAT Reagent ... Protein ID and Quantitation ... Electrophoresis (PAGE), isotope-coded affinity ... technology to facilitate the ...
Supplemental reagent for annexin V assay....
Biology Products: